News from SGC

Posted on Saturday 7th of June 2014

A news article in this week's Nature Medicine entitled "Patent-free pact pushes the boundaries of precompetitive research" highlights the work of the SGC's precompetitive public-private partnership model that requires an agreement to make all output freely available to the public without any restriction on use, such a the development of patents.

Posted on Saturday 7th of June 2014
The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington’s disease (HD) using structural and chemical biology.
Posted on Wednesday 7th of May 2014

The Group led by Professor Chas Bountra, Chief Scientist of SGC Oxford, has been awarded the Royal Society of Chemistry's Rita and John Cornforth Award 2014 for "... world leading collaborative research across the disciplines of structural biology, medicinal chemistry, chemical biology and enzymology towards understanding and exploiting the potential of epigenetics as a target family for future drug discovery". 

Posted on Wednesday 7th of May 2014

The Group led by Professor Chas Bountra, Chief Scientist of SGC Oxford, has been awarded the Royal Society of Chemistry's Rita and John Cornforth Award 2014 for "... world leading collaborative research across the disciplines of structural biology, medicinal chemistry, chemical biology and enzymology towards understanding and exploiting the potential of epigenetics as a target family for future drug discovery". 

Posted on Tuesday 22nd of April 2014

Inhibiting bromodomains - which are small interaction modules on proteins that assemble acetylation-dependent transcriptional regulatory complexes - could be a way to alter the expression of disease-promoting genes. In a Nature Reviews Drug Discovery article, the SGC highlights recent developments in the discovery of small-molecule bromodomain inhibitors and discuss how they might be used in cancer, inflammation and viral infection.

Posted on Tuesday 25th of February 2014
The Structural Genomics Consortium (SGC) and DiscoveRx Corporation announced the publication of findings demonstrating that several clinical kinase inhibitors also potently inhibit diverse bromodomain epigenetic reader proteins. This study titled “Dual kinase-bromodomain inhibitors for rationally designed polypharmacology”, which appears on-line today in Nature Chemical Biology , suggests compelling new multi-targeting approaches for cancer therapy.
Posted on Thursday 19th of December 2013
Bayer Inc. is pleased to announce that Bayer HealthCare has joined the SGC, a not-for-profit, public-private partnership with active research facilities at the Universities of Toronto and Oxford, UK.
Posted on Tuesday 26th of November 2013
The Open Access nature of SGC work is discussed in this article on CreativeCommons.org

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03